Psilocybin research and rule-change news
What changed, when, and where it's written down: potency and label rules, interaction research, trials and federal actions, each linked to the primary document.
We add two to four posts a month. Each one links to the rule text, filing, study or agency release it reports, and none of them gives dosing advice.
- Oregon's draft psilocybin rules add a new potency line to product labels
Oregon's draft rules add a total psilocybin equivalent label line and, under HB 4040, split dose reporting.
- Oregon proposes changing the formula labs use to total psilocybin potency
Oregon labs would report "total psilocybin equivalent" instead of "total potential psilocin".
- Microdosing meta-analysis finds no clear benefit over placebo in healthy adults
Pooled randomized trials showed no significant effect on depression, anxiety or stress scores versus placebo.
- Fourteen Psilocybe cubensis strains grown the same way differed almost tenfold in psilocybin
A 2026 study of 14 cubensis strains found psilocybin varied 9.66-fold, and single mushrooms of one strain differed too.
- Young children's psilocybin product ingestions reported to poison centers rose sharply from 2018 to 2024
Poison center rates for children under 6 rose from 0.06 to 0.94 per 100,000 between 2018 and 2024.
- New Mexico holds psilocybin rules hearing as labels move to two potency totals
October 2 hearing on medical psilocybin rules; producer rules would put two potency totals on every label.
- DEA proposes adding five tryptamine hallucinogens to Schedule I
4-OH-DiPT, 5-MeO-AMT, 5-MeO-MiPT, 5-MeO-DET and DiPT would join psilocybin in Schedule I.
- FDA holds a public hearing on how approved psychedelic drugs could be used
FDA asked how clinics and state programs should record drug, dosage and setting the same way.
- Compass reports one-year COMP360 psilocybin data and keeps its FDA filing on track for late 2026
One-year open-label COMP005 results, and an FDA application Compass says it will complete by the end of 2026.
- Colorado creates a natural medicine sales license for healing centers
HB26-1325 and emergency rules took effect August 12. How Colorado tests psilocybin and labels it in Total Psilocin.
- FDA finalizes its guidance for clinical trials of psychedelic drugs
FDA's final guidance names SSRIs, lithium and tricyclics as interactions trial sponsors should plan for.
- CDC's report on Diamond Shruumz chocolate illnesses: 180 cases, 73 hospitalized, 2 deaths
MMWR, April 9, 2026: 180 cases, 38 ICU admissions, 29 intubations, 2 deaths. CDC's 2024 count, shown by FDA, was 3.
Follow along with the RSS feed.